In this episode of MATCH B2B Insights, we break one of the most misunderstood topics in B2B growth: branding.

Not as visuals. Not as storytelling.

If your market hears you but doesn’t trust you, understand you, or place you fast enough inside a buying decision - that’s not a design issue. That’s friction. And friction kills pipeline.

In this episode, we cover:

This episode is built for operators:

If you're struggling with low conversion, long sales cycles, or weak differentiation - this is not a marketing problem.

Most cybersecurity deals don’t get lost.

In this episode of MATCH B2B Insights, Benny Fluman, Dafna Cohen, and Nadav Berkovich break down one of the most frustrating patterns in cyber sales: strong interest, solid demos, even successful POCs - and then… nothing moves.

The problem is rarely the product.

As discussed in the episode, deals don’t progress because one person is interested. They progress when the buying organization starts moving together.

In this conversation, we cover:

If you’re seeing deals stretch, stall, or disappear after strong early engagement,

👉 If you have deals stuck after demo, POC, or internal approval stages, you can schedule a short meeting here to review your current deal motion:

👉 For Israeli companies operating in this complex period, there is a dedicated support package for small businesses, supported by government funding, designed to help execute international marketing and demand generation programs:

Most cybersecurity companies don’t have a pipeline problem.

In this episode of MATCH B2B Insights, we break down why strong cyber companies stay busy but fail to build predictable demand. From outbound and SDR to content, paid media, and events - everything can look active, while the pipeline itself remains weak.

The core issue is not effort. It’s how that effort connects.

We explore:

This is a practical conversation for founders, CEOs, and GTM leaders who want to move from random traction to a repeatable demand engine.

👉 Schedule a short meeting to explore how to build a predictable pipeline system:

👉 For Israeli companies operating in this challenging period, there is a dedicated support track for small businesses, including special assistance programs:

Most cybersecurity founders believe that staying in stealth preserves momentum.

In this episode of MATCH B2B Insights, Benny Fluman and Brenda break down a critical mistake early-stage cyber companies make - assuming that launch creates demand.

It doesn’t.

Buyers don’t discover. They filter.

This conversation goes deep into:

If you’re building a cybersecurity company and relying on launch to “create momentum”,

👉 To explore how to build early trust and a predictable pipeline, you can schedule a short meeting here:

👉 For Israeli companies operating in this complex period, there is also a dedicated support track for small businesses, including special assistance programs:

Most cybersecurity companies don’t lose deals because of weak products.

In this episode of MATCH B2B Insights, Benny Fluman and Daniel Weiss break down one of the most expensive problems in B2B today: generic messaging.

Why do strong cyber companies sound identical?

This is not a branding conversation.

You’ll learn:

If your company feels technically strong but commercially generic,

👉 In the episode description, you’ll find a link to schedule a short meeting with us.

For Israeli companies, there is currently a special support track due to the war,

In early-stage B2B, most founders treat stealth mode as a period of silence.

That’s a mistake.

Stealth is not about hiding. It’s about controlled exposure, trust-building, and preparing your market before you officially launch.

In this episode of MATCH B2B Insights, Benny Fluman, Daniel Weiss, and Brenda break down what stealth mode actually means from a commercial perspective - and why companies that wait until launch to think about marketing, positioning, and pipeline are already behind.

The conversation goes deep into:

This episode is especially relevant for:

If you’re waiting for launch to “start marketing” - this episode will challenge that assumption.

Because in B2B, trust doesn’t start at launch. It starts the moment someone hears your name.

FDA approval feels like the finish line. It’s not.

In this episode, we break down one of the most dangerous assumptions in MedTech go-to-market: that regulatory approval leads to commercial success.

It doesn’t.

We introduce the concept of buyability - the real-world ability of hospitals and healthcare systems to adopt, pay for, and implement a product under actual economic and operational conditions.

You’ll hear why:

We also unpack how hospital decisions actually happen including the role of Value Analysis Committees (VAC), budget ownership, procurement dynamics, and the hidden reasons deals quietly die.

If you're a MedTech founder, CEO, or commercial leader operating in the U.S. market, this episode will challenge how you define pipeline, traction, and growth.

Because approval gives you permission to sell.

רוב החברות הישראליות שמנסות להיכנס לשווקים בינלאומיים לא נכשלות בגלל מוצר.

יש פעילות - פוסטים, outreach, לפעמים קמפיינים -

בפרק הזה שלושה אנשים עם זוויות שונות - שיווק, מכירות ו-revenue - מפרקים את אחת הבעיות הכי שכיחות אצל חברות SMB B2B:

הדיון לא נשאר ברמת הדעה.

אנחנו מציגים מודל ברור:

ומראים למה רוב החברות עושות בדיוק הפוך.

לא תיאוריה.

📊 חשוב:

למצגת:

מה תמצאו בפרק:

למה פיזור אנרגיה מסוכן יותר ממחסור בתקציב

מה ההבדל בין ICP אמיתי לבין פילטר גנרי

איך מזהים Trigger Events אמיתיים

המחלוקת האמיתית - Authority מול Data

איך נראה יום עבודה lean של SDR

Benchmarks אמיתיים לפעילות משולבת AI ו-SDR

כמה מספיק בפרופיל ובאתר

השאלה המרכזית:

האם חברה קטנה יכולה לבנות pipeline בינלאומי יציב בלי צוות שיווק גדול?

אם אתם מרגישים שאתם עושים הרבה אבל לא בונים מערכת,

In this episode of MATCH B2B INSIGHTS, Benny Fluman and Brian Newman break down why so many Medtech companies with strong technology still struggle to build a predictable commercial engine. The conversation focuses on a problem many CEOs and Business Development leaders know well: pipeline that depends on conferences, referrals, and founder relationships instead of a repeatable system.

The discussion explores how hospital and provider buying behavior has become more cautious, more operationally driven, and less responsive to innovation messaging alone. Benny and Brian explain why Medtech companies now need to sell not just product novelty, but adoption, workflow fit, implementation logic, and realistic ROI.

Drawing on current market signals and ongoing conversations with Medtech companies in the U.S., the episode highlights the structural issues behind stalled demos, slow post-conference follow-up, CEO-dependent selling, and inconsistent deal flow. It also outlines what a repeatable commercial system actually requires, from ICP clarity and customer journey design to messaging discipline and business-outcome framing.

If the patterns in this episode feel familiar, listeners are invited to contact Brian Newman for a practical diagnostic conversation about where pipeline is breaking, what process changes may be needed, and what realistic ROI expectations should look like.

Email: [email protected]

איך סטארטאפ מוצא את הלקוחות הראשונים שלו - ולא מבזבז חודשים על פגישות לא נכונות, מסרים חלשים או פיילוטים שלא נסגרים לעסקה?

בפרק הזה של MATCH B2B Insights אנחנו צוללים לעומק הדרך שבה סטארטאפים יכולים לבנות מסע לקוח אפקטיבי שמוביל לשיחות עם הלקוחות הנכונים, לפיילוטים מדויקים, ולמכירות הראשונות.

נדבר על מושגים מרכזיים כמו ICP, Customer Discovery, Qualification, Pilot Design, Product-Market Fit ו-Go-To-Market, אבל בשפה ברורה שמתאימה במיוחד למייסדים שנמצאים בתחילת הדרך.

הפרק כולל דוגמאות מהשטח, טעויות נפוצות שחוזרות אצל סטארטאפים, והסבר מעשי איך לבנות מנגנון רזה שמייצר שיחות איכותיות עם לקוחות פוטנציאליים ומגדיל את הסיכוי להגיע לפיילוטים וללקוחות משלמים.

בסיום הפרק נסביר גם כיצד MATCH B2B מסייעת לחברות צעירות לבנות מנגנון שיווקי-מכירתי ראשוני ומדויק, ולהכין את הקרקע לצמיחה, Bootstrap או גיוס.